Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Buy” from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been given a consensus recommendation of “Buy” by the seven analysts that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $11.40.

RVPH has been the topic of several research analyst reports. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, January 10th. HC Wainwright cut their target price on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, January 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after purchasing an additional 42,376 shares during the period. EMC Capital Management raised its holdings in shares of Reviva Pharmaceuticals by 142.0% in the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after buying an additional 26,134 shares during the period. Drive Wealth Management LLC bought a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $36,000. Ameriprise Financial Inc. purchased a new position in Reviva Pharmaceuticals during the 4th quarter valued at $84,000. Finally, Tang Capital Management LLC bought a new position in Reviva Pharmaceuticals in the 4th quarter valued at $308,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ RVPH opened at $1.44 on Friday. The stock has a market cap of $48.16 million, a PE ratio of -1.30 and a beta of -0.12. Reviva Pharmaceuticals has a 1 year low of $0.60 and a 1 year high of $4.28. The firm has a fifty day moving average price of $1.81 and a 200-day moving average price of $1.46.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.